

EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001 Tel: 022-49738167/68 Email: enquiries@ebnl.org Site: www.ebnl.org Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2018/S-2408 2018

May 28,

Dept. of Corporate Services
The Stock Exchange, Mumbai

1st floor, New Trading Ring, Rotunda Bldg
Phiroze Jeejebhoy Towers, Dalal Street
Fort, Mumbai – 400 001.
Fax No. 22723121 Email ID: corp.relations@bseindia.com

Dear Sir,

Ref: Scrip Code No. 524768
Sub: Press Release of Board Meeting Notice, as per SEBI [LODR]
Regulations, 2015.

Pursuant to Regulation 30(1) of the SEBI [LODR] Regulations, 2015, please find enclosed herewith copies of newspaper advertisement published on May 18, 2018, pursuant to Regulations 47 of the SEBI [LODR] Regulations, 2015 in relation to the Audited Financial Results for the year ended March 31, 2018.

You are requested to take the above on your record and acknowledge the same.

Thanking you,

Yours faithfully, For Emmessar Biotech & Nutrition Ltd

I.J. Pereira

Compliance Officer



Emmessar Biotech & Nutrition Ltd.

Registered Office: Plot No.T-3/2, MIDC, Taloja, Raigad Dist., Maharashtra - 410 208. CIN No. L24110MH1992PLC065942

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 3157 MARCH 2018

(₹ in lakhs)

	Particulars	Quarter Ended			Year Ended	
Sr. No.		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.201
		Audited	Unaudited	Audited	Audited	Audited
	PARTA					5
1	Revenue from Operations	3.80	12.76	73,06	131.50	270.22
2	Other Income	30.82	31.68	32.74	126.55	97.53
	Total Income (1 + 2) A	34.62	44.44	105.80	258,05	367.75
- 1	PART 8					
3	Expenses			100	The second	
	(a) Cost of material consumed	1.38	0,50	13.23	40.63	77.8
	(b) Excise on sale of goods			0.57	6.20	6.93
	(c) Purchase of Stock-trade	0.00	2.89	5,92	10.28	18.74
	(d) Change in Inventories of Finished goods	(0.64)	1.87	25.08	11.69	(0.7)
To	(e) Employee Benefit Expenses	11.96	12.42	8.93	40.76	37.71
	(f) Depreciation & amortisation of Assets	2.64	1.84	0.35	5.06	1.13
	(g) Other Expenditure	10.16	5.55	18.82	63.83	106.7
	Total Expenses (a to g)	25.50	25.07	72.90	178.46	248.4
4	Profit from operations from exceptional items and taxes (A - B)	9.12	19.37	32.90	79.59	119.2
5	Exceptional Items	0.00	0.00	0.00	0.00	0.0
6	Profit / loss before tax (4 - 5)	9.12	19.37	32.90	79.59	119.2
7	Tax Expense					74 0
7	1. Current lax (MAT)	(22.00)	0.00	0.00	(22.00)	0.0
	2. Deferred tax (asset)	33.79	0.00	0.42	33.75	- 0.4
8	Net Profit / (loss) after tax (6 - 7)	20.87	19.37	32.48	91.34	118.8
9	Other comprehensive income	1.81	0.00	0.82	1.81	0.8
10	Total comprehensive income for the period and other comprehensive income	22.68	19,37	31.66	89.53	118.0
11	Paid-up Equity Share Capital	499.51	499.61	499.61	499.61	499,6
-	Face Value of the share	10.00	10.00	10.00	10.00	10.0
12	Earnings per Equity Share					
1.00	a) Basic	0.45	0.39	0.63	1.79	2.3
-	b) Diluted	0.45	0.39	0.63	1.79	2.3

The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 16th

May 2019

The financial results have been prepared in accordance with the principles and procedures of Indian Accounting
Standards (Ind AS) as notified under Companies (Indian Acgounting Standards) Rule 2015 as specified in Section 133 of

Companies Act, 2013
3 During the year the company operated in three segments ie. Healthcare, Fine Chemicals and Rent on leasehold land.
4 The company has adopted the Ind As from April 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind As 34 Interium Financial Reporting prescribed under Section 133 of Companies Act, 2013, read with relevant rules issued thereunder. The date of transition to Ind As is April 2016. The impact of transition has been accounted for in the opening reserves and the comparative

pened results have been restated accordingly.

5 There are 5 Investors complaint and all have been sorted out.

6 Previous years' figures have been regrouped wherever considered necessary.

Quarter and Year ended Segment wise Revenue Results and Capital Employed under Clause 41 of the Listing Agreement.

(₹ in lakhs)

Sr. No.	Particulars		Quarter Ended		Year Ended	
		31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
		Audited	Unaudited	Audited	Audited.	Audited
120	Segment Revenue					
	(Net Sales / Income)	THE PARTY OF THE P	1000			
	a. Healthcure	3.80	12.76	22.99	40.61	87.40
	b. Fine Chemicals	0.00	-	49.50	84.68	175.90
- 11	c. Rent on Leasehold land	30.71	30.71	30.71	122.85	92.13
	d Others	0.114	0.97	3,52	3.70	5.39
	Total:	34.62	44,44	106.72	251.84	360,82
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
	Net Sales / Income from Operations	34.62	44.44	106.72	251.84	360.82
2.	Segment Results (Profit / Loss)			WIS IN		
	before Tax and Interest	5 - 5 - T. S.				
	a. Healthcare	3.06	7.50	13.85	22.09	52.95
	b. Fine Chemicals	0.00	0.00	2,96	6.12	43,40
	c. Rent on Leasehold land	30.71	30,71	30.71	122.85	92.13
	d. Others	0.11	0.97	3.52	3.70	5.39
	Total:	33.88	39,18	51.04	154.76	193.87
1 10	Less:	الرجانا الحا	. 3	1	The same	
-	Interest	0.00	0.00	0.00	6.00	0.00
	Other Unallocable Expenditure			116		A 100
	net off Unallocable Income	24.76	19.81	19,32	75.17	75.77
	Total Profit / (loss) before Tax	9.12	19.37	31,72	79.59	118.10
3.	Capital Employed		1 5		I I I	N. III
	(Segment Assets - Segment Liabilities)		100 E	1	1	1775-33
	a. Healthcare	12.04	4.32	7.51	12.04	7.51
	b. Fine Chemicals	58.74	57.93	57.42	58.74	57,42
	c Rept on Leasehold land	65.37	67.06	67.06	65.37	67.06
	d. Others	203.63	167.83	124.51	203.63	124.51
	Total:	339.77	297.14	256.50	339.77	256.50



Statements of Assets & Liabilities (Fin				
7	Particulars	As at 31.03.2018	As at 31.03.2017	
	ASSETS			
	Non-current Assets	200		
	(a) Property Plant & Equipment	160.07	5.39	
	(b) Capital work-in-progress		80.35	
	(c) Investment Property	65.37	67.06	
	(d) Loans	1.76	1.28	
	(e) Deferred Tax Assets (net)	45.74	11.29	
	(f) Other non current assets	10.44	17.54	
=	Sub-total Non-current Assets	283.39	182.92	
	Current Assets			
	(a) Current Investments	0.66	0.63	
	(b) Inventories	8.69	31.82	
	(c) Trade Receivables	3.34	4.09	
	(d) Cash & Cash equivalents	4.09	1.44	
	(e) Bank balance other than cash & Cash equivalents	22.80	30.51	
	(f) Loans	0.35	0.31	
	(g) Income (ax assets (net)	5.94	10.62	
	(h) Other current assets	62.20	59.56	
-	Sub-total Current Assets	108.07	138.98	
-	TOTAL ASSETS	391.46	321.90	
8	EQUITY AND LIABILITIES	والإنتان والمالية		
	SHAREHOLDER'S FUNDS:	1 1 2 1	4	
	(a) Equity Share Capital	499.61	499.61	
	(b) Other Equity	(201.13)	(290.66)	
-	Sub-total Shareholder's funds	298.48	208.95	
2	Non-current Liabilities			
	(a) Other Long-term Liabilities	61.42	61.42	
	(b) Long Term Provisions	12.23	5.14	
	Sub-total Non-current liabilities	73.65	66.56	
2	Current Liabilities		THE REAL PROPERTY.	
-	(a) Borrowings	100	0.18	
	(b) Trade payables	0.73	20.47	
	(c) Other financial Liabilities	12.26	13.65	
	(d) Other current liabilities	0.73	3.51	
	(e) Short-term provisions	5.60	8.58	
	Sub-total Current Liabilities	19.32	46.21	
-	TOTAL EQUITY AND LIABILITIES	391.46	321.72	

Mumbai 16th May, 2018 By order of the Board MSR Ayyangar Managing Director





Emmessar Biotech & Nutrition Ltd.

Registered Office: Plot No.T-3/2, MIDC, Taloja, Raigad Dist., Maharashtra - 410 208. CIN No. L24110MH1992PLC065942

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 3157 MARCH 2018

(₹ in lakhs)

		E 18 70 7	Quarter Ended		Year	nded
Sr.	Particulars	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
No.		Audited	Unaudited	Audited	Audited	Audited
-	PARTA					To be at
1	Revenue from Operations	3.80	12.76	73.06	131.50	270.22
2	Other Income	30,82	31.68	32.74	126.55	97.53
	Total Income (1 + 2) A	34.62	44,44	105.80	258.05	367.75
	PARTB		الناوا			4.5
3	Expenses				10.00	
	(a) Cost of material consumed	1.38	0.50	13.23	40.63	77.81
	(b) Excise on sale of goods		100	0.57	6.20	6,92
	(c) Purchase of Stock-trade	0.00	2.89	5.92	10.28	18.74
	(d) Change in inventories of Finished goods	(0.64)	1.87	25.08	11.69	(0.71)
	(e) Employee Benefit Expenses	11.96	12.42	8.93	40.76	37.78
	(f) Dispreciation & amortisation of Assets	2.64	1.84	0.35	5.06	1.15
	(g) Other Expenditure	10.16	5.55	18.82	63.83	106.78
	Total Expenses (a to g)	25.50	25.07	72.90	178.46	248.47
4	Profit from operations from exceptional items and taxes (A - B)	9.12	19.37	32.90	79.59	119.28
5	Exceptional Items	0.00	0.00	0,00	0.00	0.00
6	Profit / loss before tax (4-5)	9.12	19.37	32.90	79.59	119.28
7	Tax Expense					
	1. Current tax (MAT)	(22.00)	0.00	0.00	(22.00)	0,00
	2. Deferred tax (asset)	33.75	0.00	0.42	33.75	0.42
8	Net Profit / (loss) after tax (6 - 7)	20.87	19.37	32.48	91.34	118.86
9	Other comprehensive income	1.81	0.00	0.82	1.81	0.82
10	Total comprehensive income for the period and other comprehensive income	22.68	19.37	31.66	89.53	118.04
13	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499,61
	Face Value of the share	10.00	10.00	10.00	10.00	10,00
12	Earnings per Equity Share	W				THE RES
12	al Basic	0.45	0.39	0.63	1.79	2.36
	b) Diluted	0.45	0.39	0.63	1.79	2.36

1 The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 16th

2 The financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards (Ind AS) as notified under Companies (Indian Accounting Standards) Rule 2015 as specified in Section 133 of

Companies Act, 2013

3 During the year the company operated in three segments ie. Healthcare, Fine Chemicals and Rent on leasehold land.

4 The company has adopted the Ind As from April 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind As 34 Interium Financial Reporting prescribed under Section 133 of Companies Act, 2013, read with relevant rules issued thereunder. The date of transition to Ind As is April 2016. The impact of transition has been accounted for in the opening reserves and the comparative period results have been restated accordingly.

5 There are 5 Investors formulated and all base heart sorted out.

Total

5 There are 3 Investors complaint and all have been sorted out.
6 Previous years' figures have been regrouped wherever considered necessary.

Quarter and Year ended Segment wise Revenue Results and Capital Employed under Clause 41 of the Listing Agreement.

256,50

339.77

256.50

	THE RESIDENCE OF THE PARTY OF T	1000 1000	Quarter Ended		Year Ended	
Sr. No.	Particulars	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.201
		Audited	Unaudited	Audited	Audited	Audited
1.	Segment Revenue			500		
	(Net Sales / Income)		Land of the land	The same		
	a, Healthcare	3.80	12.76	22.99	40.61	87.40
	b. Fine Chemicals	0.00		49.50	84.58	175.90
	c. Rent on Leasehold land	30.71	30.71	30.71	122.85	92.13
	d. Others	0.11	0.97	3.52	3.70	539
	Total:	34.62	44.44	106,72	251.84	360.82
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
2	Net Sales / Income from Operations	34.62	44.44	106.72	251.84	360.82
2.	Segment Results (Profit / Loss)	A 10.0				
	before Tax and Interest			The Same	E CAN LO	- Sec.
	a. Healthcare	3.06	7,50	13.85	22.09	52.9
	b. Fine Chemicals	0,00	0.00	2.96	6.12	43:40
	c. Rent on Leasehold land	30.71	30.71	30.71	122.85	92.13
	- d. Others	0.11	0.97	3.52	3.70	5.39
	Total:	33.88	39.18	51.04	154.76	193.87
	Less:			0.00	0.00	0.00
	Interest	0.00	0.00	0.00	0.00	0.01
	Other Unallocable Expenditure	5700	30.00	10.00	75.17	75.7
	net off Unallocable Income	24.76	19.81	.19.32	79.59	118.14
	Total Profit / (loss) before Tax	9.12	19.37	31.72	79,39	110.19
3.	Capital Employed			3000		100
	(Segment Assets - Segment Liabilities)	The second second	-		77.04	7.5
	a. Healthcare	12.04	4.32	7.51	12.04	57.4
	b. Fine Chemicals	58.74	57.93	57.42	58.74	73600
	c. Rent on Leasehold land	65.37	67.06	67.06	65.37	67.0
	d. Others	203.63	167.83	124.51	203.63	124.5



Statements of Assets & Liabilities					
		Particulars	As at 31.03.2018	As at 31.83.2017	
V	ASSETS				
	Non-current Assets	TOTAL DESIGNATION OF THE PERSON OF THE PERSO	150.07	5.39	
	(a) Property, Plant & Equipm	ent	160.07	80.35	
	(b) Capital work-in-progress		65.37	67.05	
	(c) Investment Property		1.76	1.28	
	(d) Loans		45.74	11.29	
	(e) Deferred Tax Assets (net)		10.44	17.54	
	(f) Other non current assets		283.39	182.92	
	Sub-total Non-curr	ent Assets	283.39	196.74	
2	Current Assets	The state of the s	0.66	0.63	
1	(a) Current Investments		8.69	31.82	
	(b) Inventories		3.34	4.09	
	(c) Trade Receivables		4.09	1.44	
	(a) Cach & Cash equivalents		22.80	30.51	
	(e) Bank balance other than	cash & Cash equivalents	0.35	0.31	
	(f) Loans		5.94	10.62	
	(g) Income tax assets (net)		62.20	59.56	
	(h) Other current assets		108.07	138.98	
	Sub-total Current	Assets	391.46	321.90	
	TOTAL ASSETS		391.40	321120	
8	EQUITY AND LIABILITIES	The state of the s		1	
1	SHAREHOLDER'S FUNDS:		499.61	499.61	
	(a) Equity Share Capital		(201,13)	(290.66)	
	(b) Other Faulty		298.48	208.95	
T	Sub-total Shareho	lder's funds	290,40	2330000	
2			61.42	61.42	
6	(a) Other Long-term Liabili	tles	12.23	5.14	
	(b) Long Term Provisions	The state of the s	73.65	66,56	
	Sub-total Non-cui	rent Itabilities	73.03		
3	Current Liabilities			0.18	
	(a) Borrowings		0.73	20,47	
1	(b) Trade payables		12.26	13.65	
N	(c) Other financial Liabilitie	S C ST	0.73	3.51	
	(d) Other current liabilities		5.60	8.58	
1	(e) Shart-term provisions		19.32	46.21	
1	Sub-total Current	Liabilities	391,46	321.72	
1	TOTAL EQUITY AN	ID LIABILITIES	391.40	-	

Mumbal 16th May, 2018 By order of the Board MSR Ayyangar Managing Director

